THRN: קונצנזוס שווי הוגן Thorne

The following Thorne HealthTech (THRN) quotes illustrate the price action of an asset currently valued at 8.81. Thorne HealthTech (THRN) has transitioned to a stage of organic expansion following its acquisition by an investment fund and a planned delisting. US operations remain susceptible to inflation and logistical disruptions, which are weighing on profits. The business relies on AI diagnostics and the production of premium longevity supplements.

To stress-test positions, it is critical for the investor to determine the lower bound of target quotes, which serves as the support foundation during market shocks. The current average investment bank forecast for the stock stands at 8.81, reflecting aggregated expert expectations for the valuation of Thorne HealthTech (THRN), whose resilient recurring payment model for wellness services and steady free cash flow minimize the risks of a prolonged decline.